Aardvark Therapeutics, Inc. Annual Report - How They Did This Year

Hey there! Thinking about Aardvark Therapeutics? This guide helps you understand what they've been up to this past year. It also explains what it might mean for your investment. We'll break down the important stuff in plain English, just like talking to a friend.

1. What does this company do and how did they perform this year? Aardvark Therapeutics, Inc. is a public company. You can find their shares on The Nasdaq Stock Market; look for 'AARD'. This report covers their activities up to December 31, 2025. It also includes important events through February 2026. Aardvark is a "smaller reporting company" and an "emerging growth company." This means they're still growing, unlike bigger companies. They also have fewer public reporting rules. This can mean less detailed financial information. They get more time to meet some regulatory standards.

   What they do: Aardvark is a clinical-stage biopharmaceutical company. This means they research and develop new medicines. Their products are still in human testing. They mainly create small-molecule drugs. These drugs activate the body's natural systems. They aim to treat metabolic diseases. Specifically, they target "Bitter Taste Receptors" (TAS2Rs) in the gut. This helps with hunger-related conditions.

   Their main drug, ARD-101, is an oral medicine. It works in the gut. It aims to make the body release its own hunger-suppressing hormones. These include CCK, PYY, and GLP-1. This differs from older methods. Those methods added hormones directly. They often caused safety issues, like pancreatitis. Aardvark believes ARD-101 is barely absorbed into the bloodstream. This keeps its action in the gut. It helps reduce potential side effects. ARD-101 contains denatonium acetate monohydrate. Early studies show it stays about 99% in the gut.

   A bit more about Prader-Willi Syndrome (PWS): PWS is a genetic disorder. It causes severe, life-threatening hunger, called hyperphagia. This usually starts between ages 3 and 8. It also leads to early obesity and other metabolic issues. It's a rare disease. It affects about 1 in 15,000 births worldwide. Roughly 10,000 to 20,000 patients live in the US. PWS patients often have problems with hunger hormones. These include CCK and ghrelin. ARD-101 aims to fix this imbalance.

   How they performed this year (operationally): ARD-101 made big operational progress. This happened in 2025 and early 2026.

   • They finished Phase 1 and Phase 2 clinical trials. Phase 1 tested healthy volunteers. Phase 2 tested PWS patients with extreme hunger. They completed the Phase 2 trial in early 2025.
   • In the Phase 2 PWS trial, ARD-101 was generally well-tolerated. Patients had no serious side effects. The first part showed lower hunger scores (HQ-CT 9 or HQ-CT 13). In the second part, four patients finished the trial. Their hunger scores dropped about eight points after 28 days.
   • Beyond hunger reduction, Phase 2 data showed positive body changes. Patients saw about a 1.5% decrease in body fat. They also gained over 2% lean muscle. This happened after 28 days of ARD-101 dosing. These are important health benefits.
   • Phase 2 safety was also encouraging. Side effects were generally mild to moderate. This was across both parts of the trial, involving 19 PWS patients. Importantly, no severe side effects occurred. Only one patient stopped treatment in the first part. This was due to a drug allergy at a 200 mg dose. In the second part, all side effects were mild (Grade 1). No one stopped treatment. They also saw no increase in side effect severity with higher doses.
   • A major step forward: They started their key Phase 3 clinical trial in December 2024. This is called the HERO trial, for PWS-related hunger. This is a crucial stage before getting drug approval. The FDA usually needs two successful Phase 3 trials. So, the HERO trial is a big step. This 12-week trial is randomized, double-blind, and placebo-controlled. It mainly checks ARD-101's effect on hunger using the HQ-CT questionnaire. It also reviews caregiver and doctor reports. It explores effects on body weight, muscle mass, and other health signs. To be included, patients need a confirmed PWS diagnosis and hyperphagia. Their starting HQ-CT score must be 13 or higher.
   • They actively worked with the FDA to improve their trial. In August 2025, they changed the rules. They removed some patient exclusion criteria. This included anti-psychotic use and insulin-dependent type 2 diabetes. This broadens the patient pool. In October 2025, the FDA agreed to lower the minimum age. Participants can now be 10, not 13 (announced November 2025). This helps include more patients. It could also expand the drug's market. In December 2025, they asked to lower the age further to 7 years.
   • By January 2026, they announced a milestone. They had enrolled over 50% of the 90 target patients for the HERO trial.
   • They also expanded their reach. They started trial sites in Australia in late 2025. Then they added sites in the UK, South Korea, and Canada in early 2026. They also started an Open Label Extension (OLE) trial. This is for patients finishing the HERO trial.

   However, a big development recently occurred. On February 27, 2026, Aardvark voluntarily paused enrollment and dosing. This affects both the HERO and OLE trials. They paused after seeing "reversible cardiac observations." These are heart changes that can be undone. They saw them in a separate study with healthy volunteers.

   Here's what happened: In February 2026, they ran a study. It checked heart safety in healthy volunteers. The first group got a very high dose (1600 mg twice daily). They did not gradually increase the dose. Two of eight participants showed big increases in "QRS duration." This measures heart electrical activity. One more had a smaller increase. These observations were not serious side effects. They also had no severe heart symptoms. The HERO trial uses gradual dose increases (200mg, 400mg, then 800mg). They saw no such heart signals in earlier trials. This includes Phase 1, Phase 2, or animal studies. A follow-up group got the target dose (800 mg twice daily). They also did not gradually increase the dose. Two of 23 participants showed similar, temporary QRS increases. Again, these were not serious side effects or severe symptoms. Potentially good news: Early analysis links higher ARD-101 blood levels to more QRS changes. However, at lower doses, like 200 mg twice daily, drug levels are much lower. These lower levels are below where heart changes occurred. This matches their Phase 2 trial. There, they found no significant heart issues at lower doses. Aardvark believes they can manage safety. They will monitor drug levels and heart activity. They still believe ARD-101 can be given at a dose that helps patients. This dose will also be acceptably safe.

   They are now reviewing all data. They work closely with the FDA to plan next steps. This means original plans might change. This includes trial design, timelines, and future clinical plans. They no longer expect main HERO trial results in late 2026. This was their previous plan.

   This pause also affects ARD-201, their other drug program. It combines ARD-101 with another obesity drug. They started a Phase 2 POWER trial in December 2025. They planned a STRENGTH trial for early 2026. ARD-101 is part of ARD-201. So, they also voluntarily paused these ARD-201 trials. They will assess safety and talk with the FDA. They expect to give more updates in mid-2026.

   Other Programs: Beyond ARD-101 and ARD-201, Aardvark develops other programs. These target conditions with high unmet needs. Some drugs also target TAS2Rs. They also have a separate clinical program. It is not TAS2R-related. It's a low-dose, liquid, extended-release naltrexone. This treats autism. Looking ahead, Aardvark protects its ideas with patents. These cover other uses for their main compounds. This includes fatty liver diseases (patents expire 2041). It also covers severe acute respiratory syndrome, a serious lung condition (patents expire 2042). They also work on drug forms that are harder to abuse (patents expire 2043). They hold a patent for treating COVID-19 cognitive issues (expires 2041). This shows they explore many future medicines. Their focus goes beyond current main projects.

2. Financial performance - revenue, profit, growth metrics Aardvark is a clinical-stage biopharmaceutical company. They have no approved products yet. So, they earn no money from product sales. Therefore, the company is not profitable now. This is normal for drug development companies. Their financial health mainly shows big research and development costs. It also shows their ability to raise money for these operations.

   As of June 30, 2025, regular investors held about $162.9 million in stock. This excludes shares held by company insiders. This was based on a $13.52 share price on Nasdaq. Also, as of February 28, 2026, about 21.8 million shares were available to trade.

   Important Funding News: In February 2025, Aardvark completed its Initial Public Offering (IPO). This is when a private company first sells shares to the public. They sold shares at $16.00 each. They received about $87.5 million in net proceeds. This is money left after expenses. Before their IPO, they had already raised $129.1 million. This came from various investors. It included an $85.0 million Series C funding round in May 2024.

3. Major wins and challenges this year Major Wins (prior to the pause):

   • Successful Clinical Progress: They finished Phase 1 and Phase 2 trials for ARD-101. The drug was well-tolerated. It positively affected hunger in PWS patients. They completed the Phase 2 trial in early 2025.
   • Positive Phase 2 Safety: Side effects were generally mild to moderate in the Phase 2 trial. No severe side effects occurred across 19 PWS patients. This is a good sign for the drug's safety at those doses.
   • Improved Body Composition: Phase 2 data also showed good trends. Patients saw 1.5% less body fat. They gained 2% more lean muscle. This happened after 28 days of ARD-101 dosing. These are important health benefits.
   • Advanced to Phase 3: They started the key Phase 3 HERO trial for ARD-101 in PWS in December 2024. This is a big step in drug development.
   • Strong Enrollment: By early January 2026, they enrolled over 50% of the 90 target patients. This showed good momentum for their Phase 3 trial.
   • Expanded Market Opportunity: They worked with the FDA to change their trial rules. In August 2025, they removed some exclusion criteria. In October 2025, they got approval to lower the minimum age. Patients can now be 10, not 13. (They asked in December 2025 to lower it to 7). This expands the potential patient base for ARD-101.
   • International Expansion: They opened trial sites in new countries. These include Australia (late 2025), the UK, South Korea, and Canada (early 2026). This helps recruit patients and expand globally.
   • Successful IPO: They raised $87.5 million in net proceeds from their IPO in February 2025. This provided important money for their operations.

   Challenges:

   • Voluntary Clinical Trial Pause (The Big One): On February 27, 2026, they paused their main Phase 3 HERO trial and the OLE trial. This happened after seeing "reversible cardiac observations." These are heart changes from a separate healthy volunteer study. Specifically, QRS duration increased at higher doses. This occurred at 1600 mg twice daily in 2 of 8 subjects. It also happened at 800 mg twice daily in 2 of 23 subjects. These were not serious side effects. The company believes a safe and effective dose exists. Still, this is a serious setback. It creates uncertainty and delays.
   • ARD-201 Program Pause: Their promising obesity program, ARD-201, also paused. It includes ARD-101. This means the POWER trial, started in December 2025, won't have early data in late 2026. The STRENGTH trial won't start in early 2026 as planned.
   • Delayed Timelines: The pause invalidates the HERO trial's previous timeline. This includes main data in late 2026. This pushes back potential drug approval and sales.
   • Operational Delays: Expanding staff and operations may be delayed. They are evaluating next steps.
   • Drug development has many hurdles. As a clinical-stage company, they face risks. These relate to trial success, regulatory approvals, and competition.

4. Financial health - cash, debt, liquidity Funding operations and trials is critical for the company. Their February 2025 IPO brought $87.5 million in net proceeds. This greatly boosted their cash. This cash is crucial for funding trials and operations. Before the IPO, they already raised significant money. This included $129.1 million from various investors. A notable $85.0 million Series C funding round happened in May 2024. Drug development is costly. The trial pause adds to this. The company's future cash flow depends on managing expenses. They may need to secure more funding if needed.

5. Key risks that could hurt the stock price The company says this report contains "forward-looking statements." These involve "substantial risks and uncertainties." This means they have future plans and hopes. But many "what ifs" could affect their success. Some big risks they point out include:

   • Clinical Trial Success (Now a Reality): There's no guarantee trials will succeed. They might not show safety or effectiveness. They might not finish on time. The voluntary pause of HERO and ARD-201 trials on February 27, 2026, shows this risk. This pause was due to reversible heart changes. Companies must report trial progress to the FDA annually. More importantly, they must immediately report 'Serious and Unexpected Suspected Adverse Reactions.' The heart observations are an example. This strict rule caused the pause. The company must investigate and report safety signals. Aardvark believes a safe dose can be found. Still, this creates big uncertainty. It affects their main programs' future. It impacts their ability to resume and finish trials. The ARD-201 pause specifically delays their promising obesity treatments.
   • Regulatory Approval: Getting a drug approved by the FDA is long and uncertain. This includes other international regulators. Current FDA talks about the trial pause show this uncertainty. There's no guarantee of approval. This is especially true with new safety questions. This holds even if the company believes a safe dose exists. Even if approved, the FDA might ask for more studies. These 'Phase 4' trials check safety after the drug is sold. Not doing them could withdraw approval. This adds another risk.
   • Competition: The drug industry is very competitive. Other companies might make better or cheaper treatments.
   • Funding: Drug development companies need much money for research and trials. Delays from the pause could mean needing more cash for longer. There's a risk they won't get enough funding. Their current cash might not be enough.
   • Reliance on Others: They rely on outside companies. These companies run trials and make their drugs. This adds risks if partners don't perform. Their own staffing expansion delay also adds to this.
   • Intellectual Property: Protecting drug ideas with patents is crucial. Their patents might not be strong enough. They could also face challenges. Patents usually last 20 years from filing. But extensions are possible, especially for FDA-approved drugs. The Hatch-Waxman Act allows up to five extra years. However, regulators might not grant these extensions. They might not grant them for the full time requested. This means drug protection could end sooner. This could open the door for competitors. They also use trade secrets. These are harder to protect than patents.

6. Competitive positioning Aardvark believes their approach is unique. They state: "Besides our drugs, we know of no other approved or clinical-stage drugs targeting certain TAS2Rs." This suggests a new space. They may have no direct competitors using the same method.

   They stress their approach is different. They activate TAS2Rs in the gut. This releases natural hunger-suppressing hormones. These include CCK, PYY, and GLP-1. They believe this "neural-first mechanism" reduces hunger. It does so without causing nausea. This could overcome other therapies' limits. They also note ARD-101 stays in the gut. This avoids serious side effects like pancreatitis. Older systemic drugs targeting CCK caused these. They distinguish "hunger" (avoiding pain) from "appetite" (seeking pleasure). ARD-101 targets hunger. This is key for PWS patients. PWS patients have high ghrelin levels and abnormal CCK regulation.

   One approved treatment exists for PWS hyperphagia. Aardvark notes no single therapy fully treats severe hyperphagia in all PWS patients. This suggests a big unmet need. ARD-101 aims to fill it.

   Their patent strategy shows their unique position. They protect ARD-101 for PWS. They also protect ARD-201 for obesity (patents expire 2041). They actively explore and patent their main compounds for other conditions. These include fatty liver diseases, severe acute respiratory syndrome, and abuse-deterrent drug forms. This broad approach builds a strong protective fence. It makes it harder for others to copy their methods or compounds.

   However, they admit a risk. "Competing therapies" might succeed or become available.

7. Leadership or strategy changes Big strategic changes happened. These relate to their clinical trials:

   • They successfully worked with the FDA. They amended the Phase 3 PWS trial rules. They aimed to lower the minimum age for patients from 13 to 10. (They asked in December 2025 to lower it to 7). They also removed some exclusion criteria. This strategic move broadens the patient population. It expands the potential market for ARD-101.
   • Major Strategic Shift: The voluntary pause of the HERO and ARD-201 trials on February 27, 2026, is a big, unplanned strategic shift. Their immediate strategy now focuses on reviewing safety data. They collaborate with the FDA. They must determine the path forward for their main programs. This also delayed their planned expansion of clinical management and regulatory teams.

   The management team includes Dr. Tien Lee (Founder, CEO). He has over 20 years of biotech experience. Dr. Manasi Jaiman is Chief Medical Officer. Nelson Sun is Chief Financial and Operating Officer. All bring extensive experience to the company.

8. Future outlook The recent voluntary pause heavily impacts Aardvark's future.

   • Immediate Focus: Their immediate future centers on evaluating safety observations. These came from the healthy volunteer study. They will collaborate with the FDA. This will determine next steps for ARD-101 (HERO trial) and ARD-201 programs. They expect to give more guidance in mid-2026.
   • Delayed Timelines for ARD-201: The pause means no early data for the POWER trial in late 2026. They also won't start the STRENGTH trial in early 2026.
   • Potential Path Forward: Despite the pause, the company believes ARD-101 can be given at a safe and effective dose. This is based on early analysis showing a dose-response link. This suggests they seek a solution. It could allow trials to resume. This might involve modified dosing or monitoring.
   • Delayed Timelines: The goal of finishing the Phase 3 HERO trial is now delayed indefinitely. Seeking regulatory approval is also delayed. They no longer expect main data from the HERO trial in late 2026.
   • Continued Development (If trials resume): If safety concerns are resolved and trials resume, their plans still include:
     • Completing the Phase 3 HERO trial.
     • Seeking Regulatory Approval: If Phase 3 succeeds, they will file for ARD-101 approval.
     • Further Development: They may explore more uses for ARD-101 and ARD-201.
     • Expanding Portfolio: They also aim to develop "Other Programs." These include more TAS2R-based treatments. They also have a low-dose, liquid, extended-release naltrexone for autism. Beyond these, Aardvark develops and patents other uses for their compounds. This includes fatty liver diseases (patents expire 2041). It also covers severe acute respiratory syndrome (patents expire 2042). They also create abuse-deterrent drug forms (patents expire 2043). They have a patent for COVID-19 cognitive issues (expires 2041). This shows they expand their portfolio. They find new uses for their approach. This could lead to more drugs if current challenges are resolved.
     • Manufacturing and Sales: If approved, they will manufacture ARD-101. They will also set up sales strategies to bring it to market.
     • Identifying New Candidates: They also aim to find more potential drugs or technologies. These would have market potential. They will use internal research and partnerships.

9. Market trends or regulatory changes affecting them The company actively works with regulators like the FDA. They successfully aligned with the FDA on trial rule changes. This included lowering the minimum age from 13 to 10. (They requested 7 years). This showed they can handle regulatory processes. They can adapt to requirements. This is crucial in the drug industry. However, the voluntary pause and FDA discussions are critical. This regulatory interaction will greatly shape their future. Strict rules govern this interaction. Companies must submit annual trial reports to the FDA. More importantly, they must immediately report 'Serious and Unexpected Suspected Adverse Reactions.' The heart changes in the healthy volunteer study are an example. This ensures patient safety comes first. But unexpected findings can cause big delays. They can also change trial plans, as Aardvark now experiences. They also mention future "regulatory and legal developments." These could impact them in the US and other countries.